Sinovac Biotech Ltd Market Cap ($642.44 Million)
Market Cap & Net Worth: Sinovac Biotech Ltd (SVA)
Sinovac Biotech Ltd market cap. Sinovac Biotech Ltd (NASDAQ:SVA) has a market capitalization of $642.44 Million ($642.44 Million) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10716 globally and #2845 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sinovac Biotech Ltd's stock price $6.47 by its total outstanding shares 99294704 (99.29 Million).
Sinovac Biotech Ltd Market Cap History (2024–2026)
Sinovac Biotech Ltd market cap history from 2024 to 2026. Data shows growth from $642.44 Million to $642.44 Million (0.00% CAGR). Check Sinovac Biotech Ltd share price for real-time trading data and today's change.
Index Memberships
Sinovac Biotech Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.02% | #297 of 976 |
Weight: Sinovac Biotech Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sinovac Biotech Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sinovac Biotech Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Sinovac Biotech Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
1.66x
Sinovac Biotech Ltd's market cap is 1.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $642.44 Million | $361.37 Million | $90.91 Million | 1.78x | 7.07x |
| 2025 | $642.44 Million | $386.01 Million | -$59.68 Million | 1.66x | N/A |
Competitor Companies of SVA by Market Capitalization
Companies near Sinovac Biotech Ltd in the global market cap rankings as of October 31, 2026. See SVA equity to assets ratio to understand what proportion of total assets are financed by equity.
Key companies related to Sinovac Biotech Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Sinovac Biotech Ltd (2024–2026)
Market capitalization of Sinovac Biotech Ltd from 2024 to today. Between 2024 and today, Sinovac Biotech Ltd's market cap moved from $642.44 Million to $ 642.44 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $642.44 Million | 0.00% |
| 2025 | $642.44 Million | 0.00% |
| 2024 | $642.44 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Sinovac Biotech Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $642.44 Million USD |
| MoneyControl | $642.44 Million USD |
| MarketWatch | $642.44 Million USD |
| marketcap.company | $642.44 Million USD |
| Reuters | $642.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sinovac Biotech Ltd
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza;… Read more